≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Reduction defects of lower limb

DOID EFO Endpoint Browser PheWeb

Q17_REDUCT_DEFECTS_LOWER_LIMB

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q72
  • Cause of death: ICD-10 — Q72

2 out of 7 registries used, show all original rules.

96

4. Check minimum number of events

None

96

5. Include endpoints

None

96

6. Filter based on genotype QC (FinnGen only)

90

Control definitions (FinnGen only)

Control exclude
Q17_CONGEN_MALFO_DEFORMAT_MUSCULOS_SYSTEM

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Q6[5-9]|Q7
Name in latin
Defectus reductionales membri inferioris

Similar endpoints

↥

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1123 543 577
Only index persons 1005 493 512
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.02
Only index persons 0.02 0.02 0.02
Median age at first event (years)
Whole population 13.45 13.58 13.09
Only index persons 13.87 14.04 13.71

-FinnGen-

Key figures

All Female Male
Number of individuals 90 52 38
Unadjusted period prevalence (%) 0.02 0.02 0.02
Median age at first event (years) 22.36 27.72 15.02

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
96
Matched controls
960
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q72.88
ICD-10 Finland
Other reduction defects of lower himb(s)
+∞
55.8
48
*
Q72.9
ICD-10 Finland
Reduction defect of lower limb, unspecified
+∞
25.1
23
*
M21.7
ICD-10 Finland
Unequal limb length (acquired)
135.6
11.7
12
*
Z3231
NOMESCO Finland
Registered nurse
3.5
8.0
39
156
N06AX21
ATC
duloxetine; oral
4.7
7.6
20
51
NFU20
NOMESCO Finland
Removal of internal fixation device from femur
24.5
6.8
9
*
Z3229
NOMESCO Finland
Other healthcare associate professional
6.0
6.4
17
33
Q72.4
ICD-10 Finland
Longitudinal reduction defect of femur
+∞
6.3
6
*
N02AX02
ATC
tramadol; systemic, rectal
3.0
6.2
42
199
Z3226
NOMESCO Finland
Physiotherapist
3.5
6.1
25
88

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
General Surgery
2 [38004447]
1.4e+00
1.5e+00
—
1.0e+50
2.8e+00
1.7e+00
1.4e+00
cases:41.18%
controls:14.20%
cases:15.29%
controls:4.02%
—
—
cases:31.76%
controls:0.00%
cases:10.59%
controls:0.71%
cases:20.24%
controls:4.33%
cases:43.75%
controls:16.58%
35
120
50
725
13
34
72
811
—
27
0
58
845
9
6
76
835
17
36
67
795
35
133
45
669
Outpatient Hospital
22 [8756]
8.7e-01
1.2e+00
2.2e+00
—
2.0e+00
1.5e+00
1.2e+00
cases:37.65%
controls:20.12%
cases:16.47%
controls:5.44%
cases:7.06%
controls:0.83%
—
—
cases:5.88%
controls:0.83%
cases:17.86%
controls:4.69%
cases:41.25%
controls:17.33%
32
170
53
675
14
46
71
799
6
7
79
838
—
5
7
80
834
15
39
69
792
33
139
47
663
Orthopedic Surgery
20 [38004465]
1.5e+00
1.7e+00
—
1.0e+50
—
1.5e+00
1.1e+00
cases:21.18%
controls:5.56%
cases:9.41%
controls:1.78%
—
—
cases:7.06%
controls:0.00%
—
—
cases:10.71%
controls:2.53%
cases:21.25%
controls:8.10%
18
47
67
798
8
15
77
830
—
6
0
79
845
—
9
21
75
810
17
65
63
737
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.3e+00
—
—
—
—
2.5e+00
2.3e+00
cases:5.88%
controls:1.66%
—
—
—
—
—
—
—
—
cases:7.14%
controls:0.60%
cases:13.75%
controls:1.62%
5
14
80
831
—
—
—
—
6
5
78
826
11
13
69
789
Physical Medicine And Rehabilitation
25 [38004468]
—
1.7e+00
—
1.0e+50
—
3.1e+00
1.6e+00
—
—
cases:8.24%
controls:1.66%
—
—
cases:10.59%
controls:0.00%
—
—
cases:19.05%
controls:1.08%
cases:20.00%
controls:4.99%
—
7
14
78
831
—
9
0
76
845
—
16
9
68
822
16
40
64
762
Outpatient Visit
OP [9202]
8.7e-01
6.6e-01
2.2e-01
—
1.5e+00
1.0e+00
1.0e+00
cases:74.12%
controls:54.44%
cases:55.29%
controls:38.93%
cases:11.76%
controls:9.70%
—
—
cases:31.76%
controls:9.75%
cases:63.10%
controls:37.91%
cases:83.75%
controls:64.46%
63
460
22
385
47
329
38
516
10
82
75
763
—
27
82
58
759
53
315
31
516
67
517
13
285
Neurology
13 [38004458]
9.3e-01
1.9e+00
—
1.0e+50
—
2.1e+00
7.2e-01
cases:11.76%
controls:4.97%
cases:11.76%
controls:1.89%
—
—
cases:9.41%
controls:0.00%
—
—
cases:14.29%
controls:2.05%
cases:13.75%
controls:7.23%
10
42
75
803
10
16
75
829
—
8
0
77
845
—
12
17
72
814
11
58
69
744
General Practice
1 [38004446]
3.6e-01
2.2e+00
—
—
—
1.8e+00
6.6e-01
cases:8.24%
controls:5.92%
cases:9.41%
controls:1.18%
—
—
—
—
—
—
cases:11.90%
controls:2.17%
cases:12.50%
controls:6.86%
7
50
78
795
8
10
77
835
—
—
—
10
18
74
813
10
55
70
747
Medical doctor
Z2221 [2001311556]
—
—
—
—
—
1.9e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:1.32%
cases:11.25%
controls:2.49%
—
—
—
—
—
7
11
77
820
9
20
71
782
Inpatient Hospital
21 [8717]
3.8e-01
6.8e-01
1.7e+00
1.0e+50
2.2e+00
1.1e+00
7.3e-01
cases:40.00%
controls:31.36%
cases:16.47%
controls:9.11%
cases:8.24%
controls:1.54%
cases:25.88%
controls:0.00%
cases:10.59%
controls:1.31%
cases:25.00%
controls:10.23%
cases:41.25%
controls:25.31%
34
265
51
580
14
77
71
768
7
13
78
832
22
0
63
845
9
11
76
830
21
85
63
746
33
203
47
599
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.1e-01
5.2e-01
—
—
2.8e+00
5.1e-01
9.1e-02
cases:10.59%
controls:9.59%
cases:15.29%
controls:9.70%
—
—
—
—
cases:9.41%
controls:0.59%
cases:13.10%
controls:8.30%
cases:20.00%
controls:18.58%
9
81
76
764
13
82
72
763
—
—
8
5
77
836
11
69
73
762
16
149
64
653
Platelets [#/volume] in Blood
26515-7 [3007461]
1.1e-01
5.2e-01
—
—
2.8e+00
5.3e-01
9.1e-02
cases:10.59%
controls:9.59%
cases:15.29%
controls:9.70%
—
—
—
—
cases:9.41%
controls:0.59%
cases:13.10%
controls:8.18%
cases:20.00%
controls:18.58%
9
81
76
764
13
82
72
763
—
—
8
5
77
836
11
68
73
763
16
149
64
653
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.1e-01
5.2e-01
—
—
2.8e+00
5.1e-01
9.1e-02
cases:10.59%
controls:9.59%
cases:15.29%
controls:9.70%
—
—
—
—
cases:9.41%
controls:0.59%
cases:13.10%
controls:8.30%
cases:20.00%
controls:18.58%
9
81
76
764
13
82
72
763
—
—
8
5
77
836
11
69
73
762
16
149
64
653
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.1e-01
5.2e-01
—
—
2.8e+00
5.1e-01
9.1e-02
cases:10.59%
controls:9.59%
cases:15.29%
controls:9.70%
—
—
—
—
cases:9.41%
controls:0.59%
cases:13.10%
controls:8.30%
cases:20.00%
controls:18.58%
9
81
76
764
13
82
72
763
—
—
8
5
77
836
11
69
73
762
16
149
64
653
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.1e-01
5.1e-01
—
—
2.8e+00
4.9e-01
9.1e-02
cases:10.59%
controls:9.59%
cases:15.29%
controls:9.82%
—
—
—
—
cases:9.41%
controls:0.59%
cases:13.10%
controls:8.42%
cases:20.00%
controls:18.58%
9
81
76
764
13
83
72
762
—
—
8
5
77
836
11
70
73
761
16
149
64
653
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.1e-01
5.3e-01
—
—
2.8e+00
5.3e-01
9.1e-02
cases:10.59%
controls:9.59%
cases:15.29%
controls:9.59%
—
—
—
—
cases:9.41%
controls:0.59%
cases:13.10%
controls:8.18%
cases:20.00%
controls:18.58%
9
81
76
764
13
81
72
764
—
—
8
5
77
836
11
68
73
763
16
149
64
653
MCH [Entitic mass]
28539-5 [3035941]
1.1e-01
5.3e-01
—
—
2.8e+00
5.3e-01
9.1e-02
cases:10.59%
controls:9.59%
cases:15.29%
controls:9.59%
—
—
—
—
cases:9.41%
controls:0.59%
cases:13.10%
controls:8.18%
cases:20.00%
controls:18.58%
9
81
76
764
13
81
72
764
—
—
8
5
77
836
11
68
73
763
16
149
64
653
Supplier / Service Provider
OMOP5117446 [33004]
-1.0e+00
—
—
—
—
—
2.7e+00
cases:5.88%
controls:14.56%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:0.62%
5
123
80
722
—
—
—
—
—
7
5
73
797
Low back symptom/complaint
L03 [2002000628]
2.7e+00
—
—
—
—
—
—
cases:9.41%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
8
6
77
839
—
—
—
—
—
—
Headache
R51.80 [2000503603]
2.5e+00
—
—
—
—
—
—
cases:8.24%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
7
6
78
839
—
—
—
—
—
—
One hour or less
ZXE00 [2001311394]
6.2e-01
2.4e+00
—
—
—
—
1.2e+00
cases:8.24%
controls:4.62%
cases:7.06%
controls:0.71%
—
—
—
—
—
—
—
—
cases:12.50%
controls:3.99%
7
39
78
806
6
6
79
839
—
—
—
—
10
32
70
770
Asthma, unspecified
J45.9 [45562456]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:0.87%
—
—
—
—
—
—
6
7
74
795
Physiotherapist
Z3226 [2001311560]
—
—
—
—
—
2.2e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:5.95%
controls:0.72%
cases:12.50%
controls:1.75%
—
—
—
—
—
5
6
79
825
10
14
70
788
Upper gastrointestinal surgery
106 [44777669]
—
1.7e+00
—
—
—
2.1e+00
1.1e+00
—
—
cases:7.06%
controls:1.30%
—
—
—
—
—
—
cases:7.14%
controls:0.96%
cases:13.75%
controls:4.86%
—
6
11
79
834
—
—
—
6
8
78
823
11
39
69
763
Other specified counselling
Z71.8 [45581061]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.25%
controls:1.75%
—
—
—
—
—
—
9
14
71
788
tizanidine; oral
M03BX02 [21604116]
1.1e+00
—
—
—
—
9.6e-01
6.6e-01
cases:16.47%
controls:6.04%
—
—
—
—
—
—
—
—
cases:8.33%
controls:3.37%
cases:17.50%
controls:9.85%
14
51
71
794
—
—
—
—
7
28
77
803
14
79
66
723
Internal Medicine
11 [38004456]
7.2e-02
1.1e+00
—
—
—
6.1e-01
5.0e-01
cases:16.47%
controls:15.50%
cases:17.65%
controls:6.63%
—
—
—
—
—
—
cases:11.90%
controls:6.86%
cases:26.25%
controls:17.71%
14
131
71
714
15
56
70
789
—
—
—
10
57
74
774
21
142
59
660
Case Management Agency
251B00000X [38004193]
2.9e-01
2.4e-01
1.1e-01
—
1.1e+00
4.6e-01
1.5e-01
cases:34.12%
controls:27.93%
cases:24.71%
controls:20.59%
cases:9.41%
controls:8.52%
—
—
cases:16.47%
controls:6.18%
cases:29.76%
controls:21.06%
cases:46.25%
controls:42.64%
29
236
56
609
21
174
64
671
8
72
77
773
—
14
52
71
789
25
175
59
656
37
342
43
460
Emergency Room Visit
ER [9203]
4.0e-01
1.0e+00
1.7e+00
1.0e+50
1.8e+00
1.0e+00
7.4e-01
cases:32.94%
controls:24.73%
cases:17.65%
controls:7.34%
cases:8.24%
controls:1.54%
cases:17.65%
controls:0.00%
cases:5.88%
controls:1.07%
cases:20.24%
controls:8.30%
cases:46.25%
controls:29.05%
28
209
57
636
15
62
70
783
7
13
78
832
15
0
70
845
5
9
80
832
17
69
67
762
37
233
43
569
Basophils/Leukocytes in Blood
30180-4 [3022096]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
—
0
13
84
818
—
Fracture of tooth, open
S02.51 [45755762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.9e-01
7.3e-01
—
—
—
8.3e-01
1.9e-01
cases:9.41%
controls:7.22%
cases:14.12%
controls:7.34%
—
—
—
—
—
—
cases:13.10%
controls:6.14%
cases:17.50%
controls:14.96%
8
61
77
784
12
62
73
783
—
—
—
11
51
73
780
14
120
66
682
Pathology report gross observation
24419-4 [3002256]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
7
80
795
Cardiology
6 [38004451]
—
—
—
—
—
1.1e+00
3.2e-01
—
—
—
—
—
—
—
—
—
—
cases:5.95%
controls:2.05%
cases:6.25%
controls:4.61%
—
—
—
—
—
5
17
79
814
5
37
75
765
Psoriasis vulgaris
L40.0 [45543370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
Gingivitis (chronic) NOS
K05.10 [2000502717]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
0
8
80
794
Other and unspecified abdominal pain
R10.4 [45568113]
8.7e-01
—
—
—
—
—
—
cases:7.06%
controls:3.08%
—
—
—
—
—
—
—
—
—
—
—
—
6
26
79
819
—
—
—
—
—
—
nystatin; vaginal
G01AA01 [21602363]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
0
8
80
794
hydroxychloroquine; oral
P01BA02 [21604889]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
85
837
—
—
—
—
—
—
rofecoxib; oral
M01AH02 [21603993]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
6
85
839
—
—
—
—
—
0
7
80
795
Examination for driving licence
Z02.4 [45552056]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.18%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
10
85
835
0
5
85
840
—
—
—
—
0
7
80
795
Emergency Room and Inpatient Visit
ERIP [262]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
84
826
—
candesartan; oral
C09CA06 [21601829]
—
1.5e+00
—
—
—
—
—
—
—
cases:5.88%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
5
12
80
833
—
—
—
—
—
Upper respiratory infection acute
R74 [2002000942]
-1.0e+50
—
—
—
—
—
1.2e+00
cases:0.00%
controls:1.66%
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:2.37%
0
14
85
831
—
—
—
—
—
6
19
74
783
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.42%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
12
85
833
0
7
85
838
—
—
—
0
6
84
825
—
loratadine; oral
R06AX13 [21603514]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:3.62%
—
—
—
—
—
0
7
84
824
0
29
80
773
Sinus symptom/complaint
R09 [2002000890]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
Appendectomy
JEA00 [2001304802]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
7
80
795
desloratadine; oral
R06AX27 [21603526]
9.0e-01
—
—
—
—
—
6.7e-01
cases:5.88%
controls:2.49%
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:3.99%
5
21
80
824
—
—
—
—
—
6
32
74
770
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
0
8
85
837
—
—
—
0
8
84
823
—
tiotropium bromide; inhalant
R03BB04 [21603296]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.87%
—
0
6
85
839
—
—
—
0
5
84
826
0
7
80
795
Restricted oral and dental health check by dental hygienist or dental assistant
SAB01 [2001310279]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
0
8
80
794
other preparations, combinations; ointment
C05AX03 [21601631]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
8
84
823
—
finasteride; oral
G04CB01 [21602675]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
Cervicobrachial syndrome
M53.1 [45567577]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
85
835
—
—
—
—
—
—
Assistance to normal delivery
MAX99 [2001306918]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Pediatric Medicine
37 [38004477]
-2.1e-01
-6.4e-01
-1.0e+50
—
—
-2.7e-01
-3.4e-01
cases:17.65%
controls:20.95%
cases:7.06%
controls:12.54%
cases:0.00%
controls:3.31%
—
—
—
—
cases:9.52%
controls:12.15%
cases:11.25%
controls:15.09%
15
177
70
668
6
106
79
739
0
28
85
817
—
—
8
101
76
730
9
121
71
681
Check up of cardiac pacemaker
XFP20 [2001303367]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
0
5
85
840
—
—
—
—
0
5
80
797
Psychiatry
26 [38004469]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:2.74%
—
—
—
—
—
—
8
22
72
780
Chronic apical periodontitis
K04.5 [45586691]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
0
5
85
840
—
—
—
0
9
84
822
—
Pure hypercholesterolaemia
E78.0 [45542771]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
85
836
—
—
—
—
—
—
Personal history of diseases of the digestive system
Z87.1 [45542474]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
0
7
84
824
—
Hypoglycaemia, unspecified
E16.2 [45591038]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
3.4e-01
—
—
—
—
—
—
cases:5.88%
controls:4.26%
—
—
—
—
—
—
—
—
—
—
—
—
5
36
80
809
—
—
—
—
—
—
Basic examination of mouth
SAA02 [2001310275]
1.3e-01
—
—
—
—
—
3.9e-01
cases:5.88%
controls:5.21%
—
—
—
—
—
—
—
—
—
—
cases:17.50%
controls:12.59%
5
44
80
801
—
—
—
—
—
14
101
66
701
Scheduled procedure
ZXD10 [2001311387]
9.8e-01
—
—
—
—
—
1.3e+00
cases:10.59%
controls:4.26%
—
—
—
—
—
—
—
—
—
—
cases:12.50%
controls:3.62%
9
36
76
809
—
—
—
—
—
10
29
70
773
Tonsillectomy
EMB10 [2001302265]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
Urology
34 [38004474]
—
—
—
—
—
—
9.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.62%
—
—
—
—
—
—
5
21
75
781
ivermectin
D11AX22 [45893486]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
6.6e-01
—
—
—
—
—
3.0e-01
cases:7.06%
controls:3.79%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:6.61%
6
32
79
813
—
—
—
—
—
7
53
73
749
Ear pain/earache
H01 [2002000475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
Otitis media, unspecified
H66.9 [45547965]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
85
836
—
—
—
—
—
—
fluticasone; nasal
R01AD08 [21605050]
4.9e-01
6.4e-01
—
—
—
—
-3.3e-02
cases:10.59%
controls:6.75%
cases:5.88%
controls:3.20%
—
—
—
—
—
—
—
—
cases:7.50%
controls:7.73%
9
57
76
788
5
27
80
818
—
—
—
—
6
62
74
740
naproxen; oral, rectal
M01AE02 [21603968]
9.5e-01
—
—
—
—
9.1e-01
7.2e-01
cases:12.94%
controls:5.44%
—
—
—
—
—
—
—
—
cases:7.14%
controls:3.01%
cases:16.25%
controls:8.60%
11
46
74
799
—
—
—
—
6
25
78
806
13
69
67
733
dexamethasone
S02BA06 [21605168]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
0
5
85
840
—
—
—
—
—
0
8
80
794
sildenafil; oral
G04BE03 [21602648]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
0
10
85
835
0
10
85
835
—
—
—
—
—
Other senile cataract
H25.8 [45605644]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
85
838
—
—
—
—
—
—
Cerebral infarction, unspecified
I63.9 [45596216]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
31
85
814
—
—
—
—
—
—
hydrocortisone
A07EA02 [21600654]
-1.7e-01
—
—
—
—
—
1.9e-01
cases:7.06%
controls:8.28%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:7.36%
6
70
79
775
—
—
—
—
—
7
59
73
743
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
3.5e-01
—
—
—
—
—
—
cases:7.06%
controls:5.09%
—
—
—
—
—
—
—
—
—
—
—
—
6
43
79
802
—
—
—
—
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
2.4e-01
3.8e-01
—
—
—
6.1e-01
-1.2e-01
cases:9.41%
controls:7.57%
cases:8.24%
controls:5.80%
—
—
—
—
—
—
cases:9.52%
controls:5.42%
cases:12.50%
controls:13.84%
8
64
77
781
7
49
78
796
—
—
—
8
45
76
786
10
111
70
691
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
—
—
—
—
—
—
2.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:7.73%
—
—
—
—
—
—
8
62
72
740
trimethoprim; oral, parenteral
J01EA01 [21602931]
—
-1.0e+50
—
—
—
—
1.5e+00
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:11.25%
controls:2.74%
—
0
8
85
837
—
—
—
—
9
22
71
780
Other complicated root filling
SGB30 [2001310390]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
nepafenac
S01BC10 [21603648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
pantoprazole; oral, parenteral
A02BC02 [21600097]
7.8e-01
1.3e+00
—
—
—
8.5e-01
4.1e-01
cases:14.12%
controls:6.98%
cases:10.59%
controls:3.08%
—
—
—
—
—
—
cases:8.33%
controls:3.73%
cases:13.75%
controls:9.60%
12
59
73
786
9
26
76
819
—
—
—
7
31
77
800
11
77
69
725
metronidazole
D06BX01 [21602096]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
7
80
795
zolmitriptan; nasal, oral
N02CC03 [21604378]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:1.25%
—
—
—
—
—
0
5
84
826
0
10
80
792
Acute appendicitis, unspecified
K35.9 [45557651]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
0
6
85
839
—
—
—
—
—
0
8
80
794
fluticasone furoate
R03BA09 [45893496]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.42%
cases:0.00%
controls:0.59%
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
0
12
85
833
0
5
85
840
—
—
0
12
84
819
—
Diabetes non-insulin dependent
T90 [2002001131]
1.5e+00
—
—
—
—
—
1.4e+00
cases:5.88%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:1.87%
5
12
80
833
—
—
—
—
—
6
15
74
787
Dry eye syndrome
H04.10 [2000502254]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
7
80
795
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
0
5
85
836
—
—
Simple examination of mouth
SAA01 [2001310274]
4.1e-02
4.3e-01
—
—
—
—
3.0e-01
cases:8.24%
controls:7.93%
cases:5.88%
controls:3.91%
—
—
—
—
—
—
—
—
cases:17.50%
controls:13.59%
7
67
78
778
5
33
80
812
—
—
—
—
14
109
66
693
Pulmonary Disease
29 [38004472]
6.2e-01
—
—
—
-1.0e+50
—
4.9e-01
cases:7.06%
controls:3.91%
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
cases:7.50%
controls:4.74%
6
33
79
812
—
—
—
0
8
85
833
—
6
38
74
764
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
1.6e-01
7.4e-01
—
—
—
1.0e+00
4.6e-02
cases:8.24%
controls:7.10%
cases:10.59%
controls:5.33%
—
—
—
—
—
—
cases:10.71%
controls:4.21%
cases:13.75%
controls:13.22%
7
60
78
785
9
45
76
800
—
—
—
9
35
75
796
11
106
69
696
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3.3e-01
1.8e-01
-1.0e+50
—
—
5.6e-01
1.5e-02
cases:8.24%
controls:6.04%
cases:5.88%
controls:4.97%
cases:0.00%
controls:0.71%
—
—
—
—
cases:8.33%
controls:4.93%
cases:11.25%
controls:11.10%
7
51
78
794
5
42
80
803
0
6
85
839
—
—
7
41
77
790
9
89
71
713
Split tooth for reasons other than trauma
K03.82 [2000502700]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.75%
—
—
—
—
—
—
0
14
80
788
Postmenopausal bleeding
N95.0 [45567872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
Malignant neoplasm of prostate
C61 [45547509]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.24%
—
—
—
—
—
—
5
18
75
784
mometasone; nasal
R01AD09 [21605051]
3.0e-02
8.9e-01
—
—
-1.0e+50
—
1.9e-01
cases:7.06%
controls:6.86%
cases:8.24%
controls:3.55%
—
—
—
—
cases:0.00%
controls:0.59%
—
—
cases:11.25%
controls:9.48%
6
58
79
787
7
30
78
815
—
—
0
5
85
836
—
9
76
71
726
candesartan and diuretics
C09DA06 [21601838]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
0
7
85
838
0
5
85
840
—
—
—
0
7
84
824
—
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
—
—
—
—
—
—
6.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:4.86%
—
—
—
—
—
—
7
39
73
763
miconazole
D01AC02 [21601921]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
85
838
—
—
—
—
—
—
lercanidipine; oral
C08CA13 [21601759]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.42%
cases:0.00%
controls:1.54%
—
—
—
—
—
—
cases:0.00%
controls:1.56%
cases:0.00%
controls:2.49%
0
12
85
833
0
13
85
832
—
—
—
0
13
84
818
0
20
80
782
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
84
825
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
8.6e-01
—
—
—
—
—
—
cases:8.24%
controls:3.67%
—
—
—
—
—
—
—
—
—
—
—
—
7
31
78
814
—
—
—
—
—
—
Pain in joint
M25.5 [45586941]
1.5e+00
—
—
—
—
—
—
cases:8.24%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
—
—
7
17
78
828
—
—
—
—
—
—
tolfenamic acid; oral, rectal
M01AG02 [21603988]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.75%
—
—
—
—
—
0
5
84
826
0
6
80
796
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
-2.0e-01
3.1e-01
—
—
—
-2.4e-01
2.8e-01
cases:16.47%
controls:19.41%
cases:11.76%
controls:8.88%
—
—
—
—
—
—
cases:5.95%
controls:7.46%
cases:35.00%
controls:28.93%
14
164
71
681
10
75
75
770
—
—
—
5
62
79
769
28
232
52
570
Epilepsy and comparable convulsive disorders
111 [2001600111]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
0
7
85
838
—
—
—
—
—
0
6
80
796
norfloxacin; oral
J01MA06 [21603013]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
84
826
—
Carpal tunnel syndrome
G56.0 [45566891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
85
832
—
—
—
—
—
—
chlorhexidine
S02AA09 [21605155]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
84
825
—
diclofenac
D11AX18 [21602355]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
0
11
80
791
nystatin
D01AA01 [21601911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
0
8
80
794
Hip symptom/complaint
L13 [2002000637]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.62%
—
—
—
—
—
—
0
13
80
789
ebastine; oral
R06AX22 [21603521]
1.5e+00
—
—
—
—
—
—
cases:8.24%
controls:1.89%
—
—
—
—
—
—
—
—
—
—
—
—
7
16
78
829
—
—
—
—
—
—
Depressive disorder
P76 [2002000870]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.87%
—
0
5
85
840
—
—
—
—
0
15
80
787
Senile nuclear cataract
H25.1 [45581628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
7
80
795
Urinary frequency/urgency
U02 [2002001138]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
4.3e-01
5.3e-01
—
—
—
—
3.3e-02
cases:16.47%
controls:11.36%
cases:5.88%
controls:3.55%
—
—
—
—
—
—
—
—
cases:15.00%
controls:14.59%
14
96
71
749
5
30
80
815
—
—
—
—
12
117
68
685
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
9.5e-01
—
—
—
—
—
—
cases:5.88%
controls:2.37%
—
—
—
—
—
—
—
—
—
—
—
—
5
20
80
825
—
—
—
—
—
—
furosemide; oral, parenteral
C03CA01 [21601518]
1.1e+00
—
—
—
—
—
—
cases:5.88%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
80
828
—
—
—
—
—
—
lisinopril; oral
C09AA03 [21601787]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
medroxyprogesterone and estradiol
G03AA17 [715900]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
84
826
—
prednisolone
A07EA01 [21600653]
9.5e-01
—
—
—
—
—
9.5e-01
cases:12.94%
controls:5.44%
—
—
—
—
—
—
—
—
—
—
cases:15.00%
controls:6.36%
11
46
74
799
—
—
—
—
—
12
51
68
751
Gastroenterology
10 [38004455]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.24%
—
—
—
—
—
—
5
18
75
784
naproxcinod
M01AE18 [40254094]
9.5e-01
—
—
—
—
9.1e-01
7.2e-01
cases:12.94%
controls:5.44%
—
—
—
—
—
—
—
—
cases:7.14%
controls:3.01%
cases:16.25%
controls:8.60%
11
46
74
799
—
—
—
—
6
25
78
806
13
69
67
733
Stomatognathic treatment, simple
SHA01 [2001310405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
7
80
795
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
—
—
—
—
—
—
6.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:3.99%
—
—
—
—
—
—
6
32
74
770
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
0
5
85
840
—
—
—
—
—
0
6
80
796
Heart failure, unspecified
I50.9 [45576879]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Infiltration anesthesia
WX110 [2001310767]
1.1e-01
—
—
—
—
—
5.6e-01
cases:7.06%
controls:6.39%
—
—
—
—
—
—
—
—
—
—
cases:17.50%
controls:10.85%
6
54
79
791
—
—
—
—
—
14
87
66
715
Monocytes/Leukocytes in Blood
26485-3 [3019069]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
—
0
13
84
818
—
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
1.5e-01
1.3e-01
—
—
-1.0e+50
-1.5e-01
2.8e-02
cases:10.59%
controls:9.23%
cases:7.06%
controls:6.27%
—
—
—
—
cases:0.00%
controls:2.26%
cases:5.95%
controls:6.86%
cases:11.25%
controls:10.97%
9
78
76
767
6
53
79
792
—
—
0
19
85
822
5
57
79
774
9
88
71
714
fluticasone; inhalant
R03BA05 [21603288]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.54%
cases:0.00%
controls:0.71%
—
—
—
—
cases:0.00%
controls:1.68%
—
—
—
0
13
85
832
0
6
85
839
—
—
0
14
84
817
—
Sterilization
Z30.2 [45609921]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
codeine and paracetamol
N02AJ06 [1123647]
6.3e-01
1.5e+00
—
—
—
—
5.9e-01
cases:11.76%
controls:6.63%
cases:7.06%
controls:1.66%
—
—
—
—
—
—
—
—
cases:13.75%
controls:8.10%
10
56
75
789
6
14
79
831
—
—
—
—
11
65
69
737
Detailed ultrasound examination of fetus including color doppler method
MA2DE [2001306835]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
zopiclone; oral
N05CF01 [21604654]
6.0e-01
—
—
—
—
—
—
cases:5.88%
controls:3.31%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
80
817
—
—
—
—
—
—
Contraception intrauterine
W12 [2002001212]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
85
837
—
—
—
—
—
—
Other and unspecified skin changes
R23.8 [45573020]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
Pain in limb
M79.6 [45587063]
—
—
—
—
—
—
5.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:3.62%
—
—
—
—
—
—
5
29
75
773
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
fluticasone, combinations
R01AD58 [43534837]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.07%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
0
9
85
836
0
5
85
840
—
—
—
0
8
84
823
—
General anesthesia, balanced
WX408 [2001310808]
1.6e+00
—
—
—
—
-1.0e+50
—
cases:5.88%
controls:1.30%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
5
11
80
834
—
—
—
—
0
8
84
823
—
betamethasone
A07EA04 [21600656]
—
—
-1.0e+50
—
—
—
5.4e-01
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:6.25%
controls:3.74%
—
—
0
5
85
840
—
—
—
5
30
75
772
Fall on same level involving ice and snow
W00 [45756242]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
Mouth breathing
R06.5 [45573006]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Sampling
SPAT1263 [2001700364]
—
—
—
—
—
—
7.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:4.24%
—
—
—
—
—
—
7
34
73
768
Dermatitis, unspecified
L30.9 [45572271]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
85
836
—
—
—
—
—
—
Teeth/gum symptom/complaint
D19 [2002000318]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
8
84
823
—
rizatriptan; oral
N02CC04 [21604379]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
5
85
840
0
5
85
840
—
—
—
0
6
84
825
—
ispaghula (psylla seeds); oral
A06AC01 [21600555]
—
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:2.37%
—
—
0
5
85
840
—
—
—
0
19
80
783
Knee X-ray examination without contrast
NG1AA [2001308049]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
84
826
—
Nursing episode
950 [44777714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
12 lead EKG panel
34534-8 [3044889]
—
1.1e+00
—
—
—
—
3.2e-01
—
—
cases:5.88%
controls:2.13%
—
—
—
—
—
—
—
—
cases:8.75%
controls:6.48%
—
5
18
80
827
—
—
—
—
7
52
73
750
Nonorganic insomnia
F51.0 [45552492]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
Coeliac disease
K90.0 [45586745]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:0.87%
0
9
85
836
—
—
—
—
0
6
84
825
0
7
80
795
dexamethasone
C05AA09 [21601613]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
0
5
85
840
—
—
—
—
—
0
8
80
794
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.0e-01
5.9e-01
—
—
—
6.7e-01
8.8e-02
cases:9.41%
controls:7.81%
cases:10.59%
controls:6.15%
—
—
—
—
—
—
cases:10.71%
controls:5.78%
cases:16.25%
controls:15.09%
8
66
77
779
9
52
76
793
—
—
—
9
48
75
783
13
121
67
681
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
8
84
823
—
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent
O24.0 [45558213]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
0
10
80
792
dydrogesterone; oral
G03DB01 [21602544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
hydrocortisone and antiinfectives
S03CA04 [21605208]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
0
9
80
793
dexamethasone; oral, parenteral
H02AB02 [21602730]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
85
833
—
—
—
—
—
—
Albumin [Mass/volume] in Urine
1754-1 [3012516]
1.4e+00
—
—
—
—
—
—
cases:7.06%
controls:1.89%
—
—
—
—
—
—
—
—
—
—
—
—
6
16
79
829
—
—
—
—
—
—
Aortic (valve) stenosis
I35.0 [45576869]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
Weakness/tiredness general
A04 [2002000145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
0
8
80
794
Coronary angiography
AN1 [2000200163]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
6
85
839
—
—
—
0
5
84
826
—
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
1.2e+00
—
—
—
—
—
1.4e+00
cases:5.88%
controls:1.89%
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:1.87%
5
16
80
829
—
—
—
—
—
6
15
74
787
Release of median nerve
ACC51 [2001300642]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
0
6
85
839
—
—
—
—
—
0
6
80
796
Telephone prescription or other care instructions
WZB00 [2001310884]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
0
8
85
837
—
—
—
0
6
84
825
—
Spirometry at the office
SPAT1059 [2001700160]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
s-atenolol; oral
C07AB11 [21601693]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.95%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
0
8
85
837
0
8
85
837
—
—
—
—
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
0
15
84
816
—
Acute bronchitis, unspecified
J20.9 [45562445]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
85
836
—
—
—
—
—
—
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
85
837
—
—
—
—
—
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
betamethasone
D07AC01 [21602120]
—
—
-1.0e+50
—
—
—
5.4e-01
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:6.25%
controls:3.74%
—
—
0
5
85
840
—
—
—
5
30
75
772
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
—
—
—
—
—
—
6.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:4.86%
—
—
—
—
—
—
7
39
73
763
chloramphenicol
S01AA01 [21603554]
—
—
—
—
—
-1.0e+50
7.4e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:8.75%
controls:4.36%
—
—
—
—
—
0
8
84
823
7
35
73
767
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
85
836
—
—
—
—
—
—
Other disorders of vitreous body
H43.8 [45533329]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
timolol, combinations
S01ED51 [21603705]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
85
838
—
—
—
—
—
—
venlafaxine; oral
N06AX16 [21604745]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.25%
—
—
—
—
—
—
5
10
75
792
melatonin; oral
N05CH01 [21604659]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
0
6
85
839
—
—
—
—
0
8
80
794
oxcarbazepine; oral
N03AF02 [21604418]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
0
5
85
840
0
5
85
840
—
—
—
—
0
6
80
796
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
84
825
—
Vaccination
SPAT1325 [2001700426]
—
-1.0e+50
—
—
—
-1.0e+50
1.2e+00
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:7.50%
controls:2.37%
—
0
10
85
835
—
—
—
0
5
84
826
6
19
74
783
lansoprazole; oral
A02BC03 [21600098]
7.9e-01
—
—
—
—
—
—
cases:8.24%
controls:3.91%
—
—
—
—
—
—
—
—
—
—
—
—
7
33
78
812
—
—
—
—
—
—
Exposure to other specified factors
X58 [45756411]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
ECG with 12 standard connections
XF400 [2001303368]
2.2e+00
—
—
—
—
—
—
cases:5.88%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
5
6
80
839
—
—
—
—
—
—
apixaban; oral
B01AF02 [43534762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Pregnancy confirmed
Z32.1 [45566418]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.50%
—
—
—
—
—
—
0
12
80
790
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Chronic maxillary sinusitis
J32.0 [45586667]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Spirometry study
18759-1 [3000492]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
phenylpropanolamine; oral
R01BA01 [21603209]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
85
837
—
—
—
—
—
—
General Practice Dentistry
1223G0001X [38003675]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
Viral intestinal infection, unspecified
A08.4 [45576230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
85
833
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
chlorhexidine
D09AA12 [21602275]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
84
825
—
salbutamol; oral, parenteral
R03CC02 [21603312]
6.6e-01
—
—
—
—
—
—
cases:9.41%
controls:5.09%
—
—
—
—
—
—
—
—
—
—
—
—
8
43
77
802
—
—
—
—
—
—
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
0
8
80
794
progesterone; oral, parenteral, rectal, vaginal
G03DA04 [21602542]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
0
6
85
835
—
—
Short blood count panel - Blood
55429-5 [40758558]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
0
9
85
836
—
—
—
0
8
84
823
—
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
0
10
85
835
—
—
—
0
7
84
824
—
metronidazole; vaginal
G01AF01 [21602392]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
7
80
795
metformin; oral
A10BA02 [21600747]
7.2e-01
7.6e-01
—
—
-1.0e+50
—
3.2e-01
cases:7.06%
controls:3.55%
cases:7.06%
controls:3.43%
—
—
—
—
cases:0.00%
controls:0.95%
—
—
cases:6.25%
controls:4.61%
6
30
79
815
6
29
79
816
—
—
0
8
85
833
—
5
37
75
765
chlorhexidine
S03AA04 [21605193]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
84
825
—
Verruca simplex
B07.9 [2000500357]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
hydrocortisone butyrate
D07AB02 [21602106]
-1.6e-01
—
—
—
—
—
1.9e-01
cases:7.06%
controls:8.17%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:7.36%
6
69
79
776
—
—
—
—
—
7
59
73
743
Sexual health counselling
SPAT1308 [2001700409]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
Physiotherapy
R4110 [2001310233]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:1.62%
—
—
—
—
—
—
7
13
73
789
clindamycin; vaginal
G01AA10 [21602372]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
84
825
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
85
830
—
—
—
—
—
—
Sensorineural hearing loss, bilateral
H90.3 [45576850]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
8
84
823
—
etodolac; oral
M01AB08 [21603948]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
cyproterone and estrogen
G03HB01 [21602617]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
8
85
837
—
—
—
—
—
0
5
80
797
ofloxacin; oral, parenteral
J01MA01 [21603008]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
insulin aspart; parenteral
A10AB05 [21600719]
—
—
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
cases:0.00%
controls:1.43%
cases:0.00%
controls:4.93%
—
—
—
—
0
9
85
836
—
0
12
85
829
0
41
84
790
—
desonide
D07AB08 [21602112]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
—
—
—
—
—
—
6.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:5.74%
—
—
—
—
—
—
8
46
72
756
Other investigative procedure of eye
XCW99 [2001301491]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
0
7
85
838
—
—
—
—
—
0
8
80
794
Hypothyroidism caused by autoimmune thyroiditis
E03.80 [2000501406]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
ranitidine; oral, parenteral
A02BA02 [21600083]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
84
825
—
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
1.4e+00
-1.0e+50
—
—
—
—
—
cases:7.06%
controls:1.78%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
6
15
79
830
0
6
85
839
—
—
—
—
—
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
20
85
825
—
—
—
—
0
6
84
825
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
—
—
—
—
—
-1.0e+50
2.9e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.68%
cases:6.25%
controls:4.74%
—
—
—
—
—
0
14
84
817
5
38
75
764
acetazolamide; oral, parenteral
S01EC01 [21603693]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
Periodontal treatment by dental hygienist
SDE02 [2001310350]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
85
835
—
—
—
—
—
—
tamsulosin and dutasteride
G04CA52 [21602673]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
hydrocortisone and antiinfectives
S02CA03 [21605175]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
0
9
80
793
budesonide; inhalant
R03BA02 [21603285]
7.3e-01
—
—
—
—
—
8.7e-01
cases:8.24%
controls:4.14%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:3.87%
7
35
78
810
—
—
—
—
—
7
31
73
771
Cough
R05 [2002000886]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
7
85
838
—
—
—
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
1.2e+00
—
-1.0e+50
—
—
—
—
cases:7.06%
controls:2.13%
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
6
18
79
827
—
0
5
85
840
—
—
—
—
Intestinal infections due to other organisms, Other organism, not elsewhere classified
0088X [2000400186]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
—
prednisolone
S01BA04 [21603621]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.1e-01
6.5e-01
—
—
—
6.3e-01
1.7e-01
cases:9.41%
controls:8.52%
cases:14.12%
controls:7.93%
—
—
—
—
—
—
cases:13.10%
controls:7.46%
cases:18.75%
controls:16.33%
8
72
77
773
12
67
73
778
—
—
—
11
62
73
769
15
131
65
671
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
rosuvastatin; oral
C10AA07 [21601862]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.54%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
0
13
85
832
0
7
85
838
—
—
—
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
7.2e-01
—
—
—
—
—
5.3e-01
cases:7.06%
controls:3.55%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:6.11%
6
30
79
815
—
—
—
—
—
8
49
72
753
risperidone; oral, parenteral
N05AX08 [21604559]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
Caries of dentine
K02.1 [45548134]
1.8e-01
—
—
—
—
—
—
cases:5.88%
controls:4.97%
—
—
—
—
—
—
—
—
—
—
—
—
5
42
80
803
—
—
—
—
—
—
Cathetrisation of vein
TPH04 [2001309597]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.37%
—
—
—
—
—
—
5
11
75
791
podophyllotoxin
D06BB04 [21602086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
5
80
797
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
3.3e-01
5.9e-01
—
—
—
8.7e-01
1.6e-01
cases:8.24%
controls:6.04%
cases:8.24%
controls:4.73%
—
—
—
—
—
—
cases:9.52%
controls:4.21%
cases:12.50%
controls:10.85%
7
51
78
794
7
40
78
805
—
—
—
8
35
76
796
10
87
70
715
Necrosis of pulp
K04.1 [45572186]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
85
837
—
—
—
—
—
—
Acute upper respiratory infection, unspecified
J06.9 [45562437]
—
—
—
—
—
—
7.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.25%
controls:5.86%
—
—
—
—
—
—
9
47
71
755
Lipid panel - Serum or Plasma
100898-6 [1761868]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.13%
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
cases:0.00%
controls:4.86%
0
18
85
827
0
9
85
836
—
—
—
—
0
39
80
763
Medication, disinfection of root canals
SGC00 [2001310392]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
85
836
—
—
—
—
—
—
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
—
—
—
—
—
—
-1.8e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:6.36%
—
—
—
—
—
—
5
51
75
751
Sleep apnoea
G47.3 [45562094]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.78%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
0
15
85
830
0
10
85
835
—
—
—
—
—
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.62%
—
—
—
—
—
—
0
13
80
789
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
6
85
839
—
—
—
—
—
itraconazole; oral, parenteral
J02AC02 [21603081]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
85
836
—
—
—
—
—
—
Base excess in Venous blood by calculation
1927-3 [3002032]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:1.12%
—
0
6
85
839
—
—
—
0
6
84
825
0
9
80
793
roxithromycin; oral
J01FA06 [21602974]
5.7e-01
—
—
—
—
—
—
cases:9.41%
controls:5.56%
—
—
—
—
—
—
—
—
—
—
—
—
8
47
77
798
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 [2002330113]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
0
13
85
832
—
—
—
—
—
codeine; oral
R05DA04 [21603399]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
Laboratory test
15220000 [4034850]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.75%
0
6
85
839
0
5
85
840
—
—
—
—
0
14
80
788
dexamethasone
S01BA01 [21603618]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
85
836
—
—
—
—
—
—
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
0
8
80
794
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
7
85
838
—
—
—
—
—
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
6
80
796
solifenacin; oral
G04BD08 [21602641]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—
cromoglicic acid
S01GX01 [21605085]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
cases:0.00%
controls:2.29%
—
—
—
—
0
5
85
840
—
—
0
19
84
812
—
Gynaecological examination
SPAT1192 [2001700293]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
7
80
795
hydroxocobalamin; parenteral
B03BA03 [21601123]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
0
5
85
840
0
5
85
840
—
—
—
—
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.1e-01
6.5e-01
—
—
2.3e+00
4.2e-01
5.3e-02
cases:7.06%
controls:6.39%
cases:10.59%
controls:5.80%
—
—
—
—
cases:5.88%
controls:0.59%
cases:8.33%
controls:5.66%
cases:15.00%
controls:14.34%
6
54
79
791
9
49
76
796
—
—
5
5
80
836
7
47
77
784
12
115
68
687
Anogenital (venereal) warts
A63.0 [45585929]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
0
9
80
793
Diabetes mellitus screening
171183004 [4064918]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
0
5
85
840
—
—
—
—
—
0
10
80
792
latanoprost
S01EE01 [21603710]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.62%
0
6
85
839
—
—
—
—
0
5
84
826
0
5
80
797
Essential (primary) hypertension
I10 [45591453]
3.7e-01
—
-1.0e+50
—
—
—
4.0e-01
cases:10.59%
controls:7.57%
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
cases:11.25%
controls:7.86%
9
64
76
781
—
0
8
85
837
—
—
—
9
63
71
739
simvastatin; oral
C10AA01 [21601856]
-2.2e-01
—
—
—
—
—
—
cases:5.88%
controls:7.22%
—
—
—
—
—
—
—
—
—
—
—
—
5
61
80
784
—
—
—
—
—
—
combinations of corticosteroids
D07XB30 [21602188]
-1.5e-01
-1.0e+50
—
—
—
-1.0e+50
-4.4e-01
cases:8.24%
controls:9.47%
cases:0.00%
controls:2.84%
—
—
—
—
—
—
cases:0.00%
controls:2.41%
cases:6.25%
controls:9.35%
7
80
78
765
0
24
85
821
—
—
—
0
20
84
811
5
75
75
727
Teeth/gum disease
D82 [2002000380]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
0
10
85
835
—
—
—
0
8
84
823
—
hydrocortisone buteprate
D07AB11 [21602115]
-1.6e-01
—
—
—
—
—
1.9e-01
cases:7.06%
controls:8.17%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:7.36%
6
69
79
776
—
—
—
—
—
7
59
73
743
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
0
9
84
822
—
pregabalin; oral
N02BF02 [955152]
1.7e+00
—
—
—
—
—
1.2e+00
cases:8.24%
controls:1.66%
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:2.37%
7
14
78
831
—
—
—
—
—
6
19
74
783
azelaic acid; ointment
D10AX03 [21602314]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.87%
—
—
—
—
—
—
0
15
80
787
Prick test
37968009 [4242723]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
85
840
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
16
45
4.07
5.31
7.3
5.0
4.38
4.92
kpa
0.83
16
45
31
164
2.31
3.37
1.8
2.3
1.31
1.27
mg/l
0.03
22
124
19
83
2.61
3.08
2.1
1.8
—
—
—
0
0
17
72
2.65
2.92
6.5
6.2
0.00
0.41
%
—
5
22
6
9
7.02
2.91
1.3
2.0
9.17
9.89
mmol/l
—
6
9
11
36
3.32
2.67
2.5
3.8
—
—
—
0
0
29
167
2.06
2.49
1.6
1.6
—
—
—
0
0
56
406
1.91
2.45
7.8
7.0
0.57
0.55
e9/l
0.42
51
360
56
407
1.90
2.42
7.9
7.1
0.04
0.04
e9/l
0.10
51
361
53
379
1.89
2.40
11.6
9.9
0.00
0.00
e9/l
0.39
46
311
5
9
5.79
2.24
1.4
1.4
22.64
35.29
ng/l
—
5
9
23
126
2.09
2.23
1.6
1.6
288.00
580.00
titre
—
5
28
38
251
1.85
2.15
1.7
1.9
—
—
—
0
0
17
84
2.24
2.11
13.7
7.3
105.18
104.81
mmol/l
0.13
17
84
5
11
4.73
1.96
1.6
2.0
1.34
1.11
mmol/l
—
5
11
13
59
2.39
1.94
25.8
12.9
—
—
—
0
0
16
80
2.20
1.93
1.6
1.3
—
—
—
0
0
42
296
1.74
1.87
4.3
8.4
1.02
1.11
inr
3.12
35
249
7
23
3.20
1.83
2.6
5.2
1.41
1.68
%
—
7
23
70
573
1.82
1.81
9.5
8.0
77.67
77.38
u/l
0.03
70
549
15
75
2.19
1.81
5.9
5.3
1.86
0.93
%
—
7
28
13
61
2.31
1.81
12.7
5.7
1.75
2.04
mmol/l
0.11
13
48
14
68
2.24
1.81
4.9
5.4
0.50
0.96
%
—
6
23
11
48
2.46
1.78
21.0
12.9
7.47
7.39
mmol/l
0.02
11
48
8
30
2.81
1.77
4.1
3.6
1.13
1.14
%
—
8
30
14
69
2.20
1.75
6.1
5.5
0.20
0.19
%
—
5
21
42
301
1.70
1.74
6.4
5.3
38.11
37.19
g/l
0.61
36
291
5
13
3.99
1.73
14.2
4.2
7.39
7.41
ph
—
5
13
36
248
1.72
1.71
8.2
7.1
—
—
—
0
0
28
180
1.78
1.68
3.6
4.2
—
—
—
0
0
33
225
1.71
1.62
2.7
2.5
45.03
55.70
u/l
1.89
33
213
42
307
1.65
1.58
2.3
2.4
—
—
—
0
0
32
218
1.70
1.57
5.0
2.9
—
—
—
0
0
49
378
1.61
1.46
3.8
2.8
—
—
estimate
—
0
0
9
41
2.32
1.41
37.7
8.0
26.11
24.90
mmol/l
—
9
41
54
432
1.57
1.34
8.6
5.0
6.26
6.19
mmol/l
0.11
54
401
21
133
1.74
1.31
6.5
3.6
21.30
141.07
ng/l
—
10
88
17
101
1.83
1.30
2.2
2.2
—
—
—
0
0
8
35
2.40
1.30
1.1
1.5
—
—
—
0
0
5
18
2.87
1.30
1.0
1.1
—
—
—
0
0
10
49
2.16
1.27
1.1
1.1
—
—
—
0
0
6
25
2.49
1.26
1.3
1.1
—
—
—
0
0
6
25
2.49
1.26
3.7
2.8
25.02
24.34
mmol/l
—
6
25
6
25
2.49
1.26
13.7
4.3
10.30
8.77
kpa
—
6
25
49
396
1.48
1.09
5.7
7.1
9.94
10.83
umol/l
0.54
49
384
33
249
1.50
1.01
3.7
2.2
—
—
—
0
0
7
37
1.96
0.96
13.0
6.1
—
—
—
0
0
8
42
1.99
0.91
19.3
6.0
24.50
24.67
mmol/l
—
8
42
6
29
2.14
0.91
4.8
3.7
0.42
0.63
%
—
6
29
27
351
0.68
0.90
2.0
2.6
—
—
—
0
0
87
812
1.76
0.88
21.9
13.0
21.74
22.29
mg/l
0.06
71
644
11
173
0.59
0.85
1.2
1.7
—
—
—
0
0
13
82
1.68
0.83
1.7
1.5
—
—
—
0
0
9
54
1.73
0.77
10.4
5.1
7.40
7.42
ph
—
9
46
30
234
1.41
0.76
1.6
1.4
2.08
2.06
g/l
0.02
24
145
38
309
1.38
0.76
2.6
1.9
99.90
97.18
pmol/l
0.18
22
163
9
57
1.64
0.73
1.2
1.2
—
—
—
0
0
28
218
1.40
0.71
8.5
4.4
7.40
7.40
ph
0.10
23
157
13
86
1.59
0.70
1.3
1.3
—
—
—
0
0
5
27
1.90
0.69
1.8
5.1
37.00
36.90
°c
—
5
27
7
44
1.64
0.66
1.3
1.8
—
—
—
0
0
90
856
1.82
0.66
25.5
15.1
72.87
74.09
umol/l
0.17
90
843
5
29
1.76
0.64
32.4
7.5
1.52
1.40
mg/l
—
5
29
8
53
1.55
0.60
1.4
1.7
—
—
—
0
0
10
66
1.58
0.55
2.4
2.4
—
19.62
—
0
5
89
851
1.63
0.52
16.4
11.1
—
—
—
0
0
13
94
1.44
0.49
1.2
1.5
—
—
—
0
0
19
148
1.35
0.48
1.6
1.3
8.21
5.01
u/ml
—
8
59
33
279
1.28
0.48
1.8
1.8
—
—
—
0
0
16
121
1.39
0.48
3.9
2.8
12.07
14.71
umol/l
0.87
16
114
13
95
1.43
0.46
1.2
1.5
—
—
—
0
0
18
140
1.35
0.46
5.9
2.7
492.44
531.75
mosm/kgh2o
0.30
18
126
13
96
1.41
0.44
1.2
1.5
—
—
—
0
0
13
96
1.41
0.44
1.2
1.5
—
—
—
0
0
8
56
1.47
0.44
1.4
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
8
61
1.34
0.41
1.3
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
2.6
—
—
—
0
0
30
259
1.23
0.36
1.4
1.4
0.98
1.12
u/ml
0.12
12
65
12
91
1.36
0.36
1.2
1.5
—
—
—
0
0
13
101
1.33
0.34
1.5
1.4
—
—
—
0
0
24
204
1.24
0.33
1.9
2.1
—
—
—
0
0
28
245
1.20
0.29
5.9
6.2
—
—
—
0
0
82
789
1.27
0.29
27.0
13.9
139.41
139.68
mmol/l
0.53
82
768
23
198
1.21
0.28
3.2
3.1
—
—
—
0
0
11
86
1.32
0.27
2.3
2.3
0.68
0.87
ug/l
—
6
39
76
729
1.20
0.25
23.9
17.1
332.34
334.28
g/l
1.03
76
729
12
97
1.27
0.24
1.9
1.2
—
—
—
0
0
5
39
1.30
0.23
1.0
1.1
1.30
1.49
g/l
—
5
39
5
40
1.26
0.23
1.0
1.1
0.88
0.88
g/l
—
5
40
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
12.9
—
0.59
—
0
11
10
80
1.28
0.21
3.6
4.0
1.94
1.82
%
—
10
75
0
12
0.00
0.21
0.0
20.1
—
1431.25
—
0
12
0
12
0.00
0.21
0.0
1.2
—
29.55
—
0
12
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
77
744
1.18
0.20
3.8
3.6
1.38
1.25
mmol/l
0.62
72
697
47
441
1.13
0.19
5.5
3.8
0.00
0.00
estimate
-0.00
17
89
46
434
1.12
0.16
5.5
3.8
0.00
0.00
estimate
-0.00
17
92
23
208
1.14
0.16
4.7
3.4
35.70
69.27
mg/l
0.65
18
137
23
208
1.14
0.16
5.0
4.0
6.65
10.50
mg/mmol
0.28
16
137
47
445
1.11
0.15
5.6
3.8
0.00
0.00
estimate
-0.00
17
86
28
258
1.12
0.14
6.4
2.9
0.00
0.00
estimate
-0.00
16
70
15
132
1.16
0.14
1.9
2.0
2.40
2.43
mmol/l
—
7
115
19
209
0.89
0.13
8.3
3.1
—
—
estimate
—
0
0
33
351
0.91
0.12
4.5
3.4
6.64
6.20
ph
1.84
18
193
27
252
1.10
0.11
4.5
3.2
17.05
27.49
ng/l
0.64
15
146
6
55
1.10
0.09
1.3
1.6
—
—
—
0
0
32
336
0.93
0.08
6.1
3.4
0.00
0.01
estimate
0.49
16
77
6
71
0.83
0.08
29.7
10.2
97.55
96.58
%
—
6
71
54
526
1.06
0.06
7.2
4.7
—
31.64
—
0
11
28
293
0.94
0.06
2.4
1.8
—
—
—
0
0
24
251
0.94
0.04
7.0
3.2
21.06
42.65
e6/l
0.42
19
201
30
290
1.05
0.03
7.2
4.1
22.84
25.56
e6/l
0.07
19
204
21
201
1.06
0.03
8.7
5.1
—
—
—
0
0
11
102
1.09
0.03
1.5
1.2
—
—
—
0
0
13
132
0.98
0.00
18.5
3.6
0.77
0.81
mmol/l
0.81
13
124
16
157
1.02
0.00
2.4
2.2
88.30
79.73
ug/g
—
10
119
9
92
0.98
0.00
5.3
3.9
4.78
10.84
umol/l
—
9
82
0
5
0.00
-0.00
0.0
7.8
—
61.84
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.2
—
254.89
—
0
9
6
68
0.87
-0.00
29.7
7.3
132.33
125.03
g/l
—
6
68
0
5
0.00
-0.00
0.0
3.6
—
68.50
—
0
5
0
8
0.00
-0.00
0.0
1.4
—
6.36
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
129.29
—
0
7
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
0.62
—
0
5
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
5
49
1.02
-0.00
1.4
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
89
0.89
-0.00
1.5
1.1
—
—
—
0
0
24
240
1.00
-0.00
5.6
3.7
0.00
0.00
estimate
-0.00
16
86
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
0.49
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
137.80
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
29.60
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint Q17_REDUCT_DEFECTS_LOWER_LIMB and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have Q17_REDUCT_DEFECTS_LOWER_LIMB.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: Q17_REDUCT_DEFECTS_LOWER_LIMB – Reduction defects of lower limb

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data